Pipeline of Drug Candidates

ContraVir is developing drug candidates for expanding market segments with high unmet need

Preclinical

Phase 1

Phase 2

Phase 3

Hepatitis B

Phase 2a

55%

Hepatitis B

Advancing into IND-Enabling Studies

20%

Shingles and Shingles-related Pain

Phase 3

85%
 

TXL™

Having demonstrated favorable safety and efficacy in Phase 1 trials, ContraVir is developing TXL™ for Hepatitis B in Phase 2 clinical studies.

CRV431

CRV431 is advancing into IND-enabling studies in preparation for potentially entering the clinic in 2017.

Valnivudine™

ContraVir is conducting a pivotal Phase 3 trial in to further explore Valnivudine’s™ potential to reduce the incidence of shingles pain and post-herpetic neuralgia.